daratumumab + hyaluronidase-fihj + dexamethasone

Daratumumab + hyaluronidase-fihj + dexamethasone is a combination therapeutic regimen primarily used for the treatment of multiple myeloma and light chain (AL) amyloidosis. The regimen is anchored by **Darzalex Faspro**, a subcutaneous formulation containing daratumumab, a human IgG1 monoclonal antibody targeting CD38, and hyaluronidase-fihj, a recombinant human hyaluronidase enzyme that facilitates subcutaneous delivery by temporarily increasing tissue permeability. Daratumumab exerts its anti-tumor effects through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and the induction of apoptosis. Dexamethasone, a potent corticosteroid, acts synergistically with daratumumab to enhance malignant cell death and is also utilized to mitigate potential injection-related reactions. This combination is often further combined with other agents such as lenalidomide, bortezomib, or pomalidomide in various lines of therapy.

Other names

subcutaneous daratumumab and dexamethasoneDarzalex Faspro and dexamethasoneDd SC